Lenalidomide Pill

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Attaya Suvannasankha

Conditions

Multiple Myeloma

Phase 2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

CompletedNCT04151667

H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma

Start: 2019-11-22End: 2026-03-16Updated: 2026-08-20

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

WithdrawnNCT04223661

Attaya SuvannasankhaMultiple Myeloma

Start: 2021-12-06End: 2023-12-31Updated: 2022-12-08

Related Papers

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Blood2025-09-222 citations

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Blood2024-11-051 citations